Tweet
A good sign for the drug's potential efficacy and 2010 bio tech funding
http://www.genengnews.com/news/bnite...?name=72432109
EyeGate Secures $22.6M to Continue Clinical Development of Iontophoretic Eye Therapy
Highlights
EyeGate Pharma raised $22.6 million in a Series D venture financing round with new and existing investors. Of the new capital, $11 million is available immediately to EyeGate, with the remainder being held in reserve.
The funds will be used to progress clinical development of EyeGate’s lead product, EGP-437, as a treatment for the signs and symptoms of dry eye syndrome. A pivotal trial evaluating this dexamethasone-derived corticosteroid solution is scheduled to start during the first half of 2010.
http://www.genengnews.com/news/bnite...?name=72432109
EyeGate Secures $22.6M to Continue Clinical Development of Iontophoretic Eye Therapy
Highlights
EyeGate Pharma raised $22.6 million in a Series D venture financing round with new and existing investors. Of the new capital, $11 million is available immediately to EyeGate, with the remainder being held in reserve.
The funds will be used to progress clinical development of EyeGate’s lead product, EGP-437, as a treatment for the signs and symptoms of dry eye syndrome. A pivotal trial evaluating this dexamethasone-derived corticosteroid solution is scheduled to start during the first half of 2010.